Xenon Pharmaceuticals Inc.
As of Oct 22, 2026, Xenon Pharmaceuticals is in Stage 4, the downtrend phase, now in week 2 (since Oct 13, 2026). It closed at $36.50, 48.6% below its 52-week high and below its 200-day average, which is falling.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is XENE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
XENE among Biotechnology230th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …230 | XENE | Stage 4 · wk 2 | 43 | −0.2% |
Xenon Pharmaceuticals: quick answers
What stage is Xenon Pharmaceuticals in?
As of Oct 22, 2026, Xenon Pharmaceuticals (XENE) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 13, 2026 and is in week 2. What the four stages mean
Is Xenon Pharmaceuticals in an uptrend?
No. Xenon Pharmaceuticals is in a Stage 4 downtrend. It trades 30.5% below its 200-day average, which is falling.
How far is Xenon Pharmaceuticals from its 52-week high?
Xenon Pharmaceuticals closed at $36.50 on Oct 22, 2026, 48.6% below its 52-week high of $70.96. Its 52-week low is $33.49.
How has Xenon Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Xenon Pharmaceuticals is down 15.2% over the past year and down 18.0% so far in 2026.
Which sector and industry is Xenon Pharmaceuticals in?
Xenon Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.